Ralaiya Hall, LPN | |
920 Fairfax Dr, Gretna, LA 70056-8101 | |
(504) 250-4214 | |
Not Available |
Full Name | Ralaiya Hall |
---|---|
Gender | Female |
Speciality | Licensed Vocational Nurse |
Location | 920 Fairfax Dr, Gretna, Louisiana |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1851665343 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
164X00000X | Licensed Vocational Nurse | 20110888 (Louisiana) | Primary |
Mailing Address | Practice Location Address |
---|---|
Ralaiya Hall, LPN 920 Fairfax Dr, Gretna, LA 70056-8101 Ph: (504) 250-4214 | Ralaiya Hall, LPN 920 Fairfax Dr, Gretna, LA 70056-8101 Ph: (504) 250-4214 |
News Archive
The researchers reveal the role of the innate immune cells, especially the dendritic cells, that cause the activation of the killer T-lymphocytes whose action is directed against the p pancreatic cells. The results obtained in mice make it possible to consider new ways of regulating the auto-immune reaction generated by the innate immune cells.
The new president of the World Bank "should come to office understanding the realities of flooded villages, drought-ridden farms, desperate mothers hovering over comatose, malaria-infected children, and teenage girls unable to pay high school tuition. More than knowing these realities, and caring to end them, the bank president should understand their causes and interconnected solutions," Jeffrey Sachs, director of the Earth Institute at Columbia University, writes in a Washington Post opinion piece.
Backed by a $5.1 million grant, University of North Carolina and University of Malawi College of Medicine physicians and scientists will launch a multi-pronged effort to combat cervical cancer in Malawi, a country in sub-Saharan Africa where cervical cancer is the leading cause of cancer death among women.
Novavax, Inc. announced today that it has received a Small Business and Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The grant from the NIAID is to support a segment of the Company's preclinical research program for the respiratory syncytial virus (RSV) particle-based vaccine.
› Verified 7 days ago